Market Cap 40.73B
Revenue (ttm) 363.71M
Net Income (ttm) -913.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -251.24%
Debt to Equity Ratio 0.57
Volume 2,551,400
Avg Vol 2,108,942
Day's Range N/A - N/A
Shares Out 213.27M
Stochastic %K 72%
Beta 1.05
Analysts Strong Sell
Price Target $204.28

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 977 9900
Address:
700 US Highway 202/206, Bridgewater, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 8:19 AM
$INSM is currently trading at $193.22, showing strong momentum with an RSI of 73.79, indicating it is in overbought territory. The price is significantly above the 30-day moving average (MA30) of $173.86 and the 50-day moving average (MA50) of $162.35, suggesting bullish sentiment but also potential for a pullback. The recent 60-day high of $197.45 presents a key resistance level, while the 60-day low of $128.02 indicates a wide trading range. Given the current conditions, a cautious approach is warranted. Consider entering a short position if the price approaches the 60D high of $197.45, with a stop loss set at $200 to manage risk. Target a move back towards the MA30 at $173.86 for the first target and the MA50 at $162.35 for the second target, allowing for a potential profit capture as the price may revert to these averages. For a more detailed analysis, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:40 PM
$INSM is currently trading at $193.22, positioned near its 60-day high of $197.45, indicating a strong upward momentum but also potential resistance. The RSI at 73.79 suggests that the stock is overbought, which could lead to a pullback. The 30-day moving average (MA30) at $173.86 and the 50-day moving average (MA50) at $162.35 provide support levels, indicating a bullish trend over the short to medium term. Given the current metrics, the directional bias is cautiously bullish, but the overbought RSI warrants caution. Suggested entry: $190.00 (if a pullback occurs). Stop: $180.00 (below the MA30). Targets: $197.00 (first target near the 60D high) and $205.00 (second target, if momentum continues). Monitor for signs of reversal or continued strength before entering. https://privateprofiteers.com
0 · Reply
ReapN
ReapN Nov. 14 at 10:42 PM
$NVAX adjuvant Matrix M 1 of 5 avail non mRNA ’gold standard’ multiple designation/use will multiply with newly developed cancer vaccines , it’s ’how’ your body absorbs the Rx laying the tracks for future revenue see $INSM 5 years ago build it up
0 · Reply
JoeB07
JoeB07 Nov. 14 at 5:59 PM
$INSM tracking the intraday ATH is 199.38. We're not there yet. Snip courtesy of YahooFinance.
0 · Reply
WAJeff
WAJeff Nov. 14 at 4:56 PM
$INSM 197.44 looks like an all-time high
0 · Reply
GolfProLife
GolfProLife Nov. 14 at 4:38 PM
$INSM solid bounce off the $664 $SPY had me spooked thinking stop loss for a second their, 💎 🙌 🚀 🌙 & $INSM just a 🐂 with steam! Closing above ATH I agree @pianoman439 a resistance point we need to break to see next leg up potentially before JPM!
0 · Reply
GolfProLife
GolfProLife Nov. 14 at 1:49 PM
$INSM thoughts on these market conditions 🐻!
0 · Reply
Gwaadin
Gwaadin Nov. 14 at 4:50 AM
$INSM I’m nervous about a market test of the 50 day and I sold out of a lot of positions the last two weeks, including several healthcare plays today (lly, pfe and pph). But I didn’t sell this. Maybe it pulls back 10 or 20%, but I don’t know… looks like a lot of strong hands here. Willing to be humbled on this one if I’m wrong.
1 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:13 AM
$INSM is currently trading at $190.96, exhibiting strong momentum with an RSI of 74.66, indicating overbought conditions. The price is significantly above the 30-day moving average (MA30) of 172.66 and the 50-day moving average (MA50) of 161.39, suggesting bullish sentiment. However, the high RSI indicates potential for a pullback. Given the recent 60-day high of 197.08, a short-term correction may occur before further upward movement. Suggested trade plan: - Entry: Consider entering on a pullback to around $185. - Stop: Set a stop loss at $180 to manage risk. - Targets: Aim for a first target at $195, with a secondary target near the 60D high of $197.08. Monitor the RSI for signs of reversal and adjust the plan accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:20 AM
$INSM is currently trading at $192.57, exhibiting a strong bullish momentum as indicated by an RSI of 77.29, suggesting overbought conditions. The price is significantly above the 30-day MA of 169.78 and the 50-day MA of 159.38, reinforcing a bullish sentiment. However, the high RSI indicates potential for a pullback. Given the 60-day high of 197.08, a target of $197.00 could be set as an initial objective, with a secondary target around $200.00 if momentum continues. A suggested entry point would be around $192.00, allowing for a potential retracement. Set a stop loss at $185.00, which is below the recent support levels and provides a buffer against volatility, as indicated by the ATR of 7.63. This trade plan capitalizes on the current upward trend while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Latest News on INSM
Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 11:16 AM EDT - 15 days ago

Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript


Insmed To Present at September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 3 months ago

Insmed To Present at September Investor Conferences


Lung Disease-Focused Insmed 'Must-Own' Name For Investors

Aug 20, 2025, 2:46 PM EDT - 3 months ago

Lung Disease-Focused Insmed 'Must-Own' Name For Investors


Josh Brown's Best Stocks in the Market: Insmed

Aug 19, 2025, 1:04 PM EDT - 3 months ago

Josh Brown's Best Stocks in the Market: Insmed


US FDA approves Insmed's lung disease drug

Aug 12, 2025, 11:42 AM EDT - 3 months ago

US FDA approves Insmed's lung disease drug


Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:20 PM EDT - 3 months ago

Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript


Is Insmed Stock Overvalued After The 45% Jump?

Jun 16, 2025, 5:05 AM EDT - 5 months ago

Is Insmed Stock Overvalued After The 45% Jump?


Insmed: Company Presses On With Further POC PAH Treatment Data

Jun 10, 2025, 4:30 PM EDT - 5 months ago

Insmed: Company Presses On With Further POC PAH Treatment Data


Insmed's blood pressure drug meets main goal in mid-stage trial

Jun 10, 2025, 7:25 AM EDT - 5 months ago

Insmed's blood pressure drug meets main goal in mid-stage trial


Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:55 PM EDT - 6 months ago

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript


Insmed: Poised For Transformation Beyond ARIKAYCE

Apr 25, 2025, 11:58 AM EDT - 7 months ago

Insmed: Poised For Transformation Beyond ARIKAYCE


PrivateProfiteer
PrivateProfiteer Nov. 15 at 8:19 AM
$INSM is currently trading at $193.22, showing strong momentum with an RSI of 73.79, indicating it is in overbought territory. The price is significantly above the 30-day moving average (MA30) of $173.86 and the 50-day moving average (MA50) of $162.35, suggesting bullish sentiment but also potential for a pullback. The recent 60-day high of $197.45 presents a key resistance level, while the 60-day low of $128.02 indicates a wide trading range. Given the current conditions, a cautious approach is warranted. Consider entering a short position if the price approaches the 60D high of $197.45, with a stop loss set at $200 to manage risk. Target a move back towards the MA30 at $173.86 for the first target and the MA50 at $162.35 for the second target, allowing for a potential profit capture as the price may revert to these averages. For a more detailed analysis, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:40 PM
$INSM is currently trading at $193.22, positioned near its 60-day high of $197.45, indicating a strong upward momentum but also potential resistance. The RSI at 73.79 suggests that the stock is overbought, which could lead to a pullback. The 30-day moving average (MA30) at $173.86 and the 50-day moving average (MA50) at $162.35 provide support levels, indicating a bullish trend over the short to medium term. Given the current metrics, the directional bias is cautiously bullish, but the overbought RSI warrants caution. Suggested entry: $190.00 (if a pullback occurs). Stop: $180.00 (below the MA30). Targets: $197.00 (first target near the 60D high) and $205.00 (second target, if momentum continues). Monitor for signs of reversal or continued strength before entering. https://privateprofiteers.com
0 · Reply
ReapN
ReapN Nov. 14 at 10:42 PM
$NVAX adjuvant Matrix M 1 of 5 avail non mRNA ’gold standard’ multiple designation/use will multiply with newly developed cancer vaccines , it’s ’how’ your body absorbs the Rx laying the tracks for future revenue see $INSM 5 years ago build it up
0 · Reply
JoeB07
JoeB07 Nov. 14 at 5:59 PM
$INSM tracking the intraday ATH is 199.38. We're not there yet. Snip courtesy of YahooFinance.
0 · Reply
WAJeff
WAJeff Nov. 14 at 4:56 PM
$INSM 197.44 looks like an all-time high
0 · Reply
GolfProLife
GolfProLife Nov. 14 at 4:38 PM
$INSM solid bounce off the $664 $SPY had me spooked thinking stop loss for a second their, 💎 🙌 🚀 🌙 & $INSM just a 🐂 with steam! Closing above ATH I agree @pianoman439 a resistance point we need to break to see next leg up potentially before JPM!
0 · Reply
GolfProLife
GolfProLife Nov. 14 at 1:49 PM
$INSM thoughts on these market conditions 🐻!
0 · Reply
Gwaadin
Gwaadin Nov. 14 at 4:50 AM
$INSM I’m nervous about a market test of the 50 day and I sold out of a lot of positions the last two weeks, including several healthcare plays today (lly, pfe and pph). But I didn’t sell this. Maybe it pulls back 10 or 20%, but I don’t know… looks like a lot of strong hands here. Willing to be humbled on this one if I’m wrong.
1 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:13 AM
$INSM is currently trading at $190.96, exhibiting strong momentum with an RSI of 74.66, indicating overbought conditions. The price is significantly above the 30-day moving average (MA30) of 172.66 and the 50-day moving average (MA50) of 161.39, suggesting bullish sentiment. However, the high RSI indicates potential for a pullback. Given the recent 60-day high of 197.08, a short-term correction may occur before further upward movement. Suggested trade plan: - Entry: Consider entering on a pullback to around $185. - Stop: Set a stop loss at $180 to manage risk. - Targets: Aim for a first target at $195, with a secondary target near the 60D high of $197.08. Monitor the RSI for signs of reversal and adjust the plan accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:20 AM
$INSM is currently trading at $192.57, exhibiting a strong bullish momentum as indicated by an RSI of 77.29, suggesting overbought conditions. The price is significantly above the 30-day MA of 169.78 and the 50-day MA of 159.38, reinforcing a bullish sentiment. However, the high RSI indicates potential for a pullback. Given the 60-day high of 197.08, a target of $197.00 could be set as an initial objective, with a secondary target around $200.00 if momentum continues. A suggested entry point would be around $192.00, allowing for a potential retracement. Set a stop loss at $185.00, which is below the recent support levels and provides a buffer against volatility, as indicated by the ATR of 7.63. This trade plan capitalizes on the current upward trend while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
twincam
twincam Nov. 13 at 12:57 AM
$INSM The large deep in-the-money call open interest on INSM across multiple strikes suggests significant institutional positioning, since this type of structure is commonly used for efficient exposure or hedging rather than retail speculation. • This pattern can appear in scenarios involving strategic positioning, including expectations of future catalysts, long-term growth, or potential corporate events. • While Insmed has been mentioned in some industry discussions as a possible acquisition candidate, there is no confirmed buyout activity, and the open-interest pattern alone does not prove an M&A event. • If a transaction were to occur, typical biotech acquisition premiums would likely place the potential deal value modestly above the current share price, but exact pricing would depend on the acquirer and negotiations.
0 · Reply
twincam
twincam Nov. 13 at 12:47 AM
$INSM 🔬💥 Big money loading long-dated calls (Jan ‘26 $180S + $220S) while hedging w/ $165 puts. Classic catalyst positioning. Major catalysts ahead: • End ‘25 – Brensocatib CRSsNP data • H2 ‘25 – TPIP PH-ILD Phase 3 start • Early ‘26 – TPIP PAH Phase 3 • 1H ‘26 – ARIKAYCE ENCORE readout Flow says institutions are quietly betting on upside into 2026. Stay alert. 🚀📈
0 · Reply
pianoman439
pianoman439 Nov. 12 at 8:11 PM
$INSM 195 is a massive number for Insmed. A close over this figure will mark an all time high and add fuel to the bullish scenario for a breakout over 200.
0 · Reply
WAJeff
WAJeff Nov. 12 at 2:42 PM
More $INSM sold 194.98, been buying any red I see here. It’s been a beast.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 12:56 AM
$INSM is currently trading at $192.57, exhibiting a strong bullish momentum as indicated by an RSI of 77.29, suggesting overbought conditions. The price is significantly above the 30-day MA of 169.78 and the 50-day MA of 159.38, reinforcing a bullish sentiment. However, the high RSI indicates potential for a pullback. Given the 60-day high of 197.08, a target of $197.00 could be set as an initial objective, with a secondary target around $200.00 if momentum continues. A suggested entry point would be around $192.00, allowing for a potential retracement. Set a stop loss at $185.00, which is below the recent support levels and provides a buffer against volatility, as indicated by the ATR of 7.63. This trade plan capitalizes on the current upward trend while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JoeB07
JoeB07 Nov. 11 at 10:14 PM
$INSM continued short covering into the end of October....
1 · Reply
Zinsinus
Zinsinus Nov. 11 at 4:48 PM
$INSM How many shares will the indexes need on the 24th and where are they coming from! 😎
1 · Reply
WAJeff
WAJeff Nov. 11 at 3:11 PM
$MDGL $INSM Two out of three worked splendidly
0 · Reply
JoeB07
JoeB07 Nov. 11 at 1:32 AM
$INSM $PLTR $NVDA Race to $300 is underway. My money is on INSM. Have fun.
0 · Reply
seankigz
seankigz Nov. 10 at 8:54 PM
$NBIS reposting because some of y'all forgot. JP Morgan bought in, Citi bought in. $CRWV And $INSM and Nebius will all be added to the MSCI world index on November 24. Funds are going to be forced to buy in. So maybe DON'T give them your shares for cheaper than you have to. Supply and demand. You have the supply, they're the demand.
2 · Reply
biolover
biolover Nov. 10 at 2:36 PM
$VKTX Names would be $VRTX $INSM $BIIB that want to get to mega size
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 9:54 PM
0 · Reply